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Available online 10 March 2008PDZK1 is a scaffold protein containing four PDZ protein interaction domains, which bind to the carboxy
termini of a number of membrane transporter proteins, including ion channels (e.g., CFTR) and cell surface
receptors. One of these, the HDL receptor, scavenger receptor class B type I (SR-BI), exhibits a striking, tissue-
speciﬁc dependence on PDZK1 for its expression and activity. In PDZK1 knockout (KO) mice there is a marked
reduction of SR-BI protein expression (~95%) in the liver, but not in steroidogenic tissues or, as we show in this
report, in bone marrow- or spleen-derived macrophages, or lung-derived endothelial cells. Because of hepatic
SR-BI deﬁciency, PDZK1 KO mice exhibit dyslipidemia characterized by elevated plasma cholesterol carried in
abnormally large HDL particles. Here, we show that inactivation of the PDZK1 gene promotes the
development of aortic root atherosclerosis in apolipoprotein E (apoE) KO mice fed with a high fat/high
cholesterol diet. However, unlike complete SR-BI-deﬁciency in SR-BI/apoE double KO mice, PDZK1 deﬁciency
in PDZK1/apoE double knockout mice did not result in development of occlusive coronary artery disease or
myocardial infarction, presumably because of their residual expression of SR-BI. These ﬁndings demonstrate
that deﬁciency of an adaptor protein essential for normal expression of a lipoprotein receptor promotes
atherosclerosis in a murine model. They also deﬁne PDZK1 as a member of the family of proteins that is
instrumental in preventing cardiovascular disease by maintaining normal lipoprotein metabolism.
© 2008 Elsevier B.V. All rights reserved.Keywords:
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SR-BI1. Introduction
Hypercholesterolemia causes cardiovascular disease (e.g.myocardial
infarction), by promoting atherosclerosis. A number of defects in human
genes encoding apoB- the apolipoprotein component of low density
lipoprotein (LDL), the LDL receptor, the LDL receptor adaptor ARH
(autosomal recessive hypercholesterolemia) or processing enzyme
PCSK9 all lead to hypercholesterolemia and atherosclerosis [1–5]. The
role of dyslipidemia in promoting atherosclerosis is commonly studied
using knockout (KO)mice, inwhich genes regulating plasma lipoprotein
metabolism have been inactivated [6]. Such models include the very
widely used apolipoprotein E (apoE) or low density lipoprotein (LDL)
receptor KO mice that exhibit robust aortic atherosclerosis, but little or
no occlusive coronary arterial atherosclerosis, and thus usually lack
other classic symptoms of coronary heart disease (CHD).s of Health HL077780 (OK),
e (JC), and HL64737, HL-52212
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her).
ase Research, Wyeth Research,
ll rights reserved.Reverse cholesterol transport, an HDL-mediated process promoting
transfer of cholesterol from peripheral tissues to the liver, is thought to
play a major role in protecting against the development of athero-
sclerosis [7]. In mice, this appears to depend, at least in part, on
expression of the HDL receptor SR-BI. SR-BI is expressed in hepatocytes,
where it mediates selective uptake of cholesterol from HDL and biliary
secretion of cholesterol [8–10], and in steroidogenic cells where
cholesterol is stored and used for the synthesis of steroid hormones
[8,11]. In the liver, normal expression of SR-BI protein is controlled by its
adaptor protein PDZK1 [12–14]. PDZK1 is a protein containing four PDZ
protein interactiondomains [15]. ThemostN-terminal of thesedomains,
PDZ1, binds to the carboxy terminus of SR-BI [13,14]. The carboxy
terminus of SR-BII, aminor splice variant of SR-BI, differs from that of SR-
BI and does not interact with PDZK1 [12,16,17]. In vivo, murine PDZK1
acts as a tissue-speciﬁc, posttranscriptional regulator of SR-BI [12]. In
PDZK1 KO mice, there is a dramatic (~95%) reduction in hepatic SR-BI
protein expression, which results in a 1.7 fold elevation of plasma
cholesterol levels carried in abnormally large HDL particles. The
abnormal lipoprotein metabolism in PDZK1 KO mice is similar to, but
not as severe as, that observed in homozygous null SR-BI KO mice (e.g.,
2.2-fold increase in total plasma cholesterol in even larger, unesteriﬁed
cholesterol-rich HDL particles) [12,18–20]. However, there are several
marked differences between SR-BI and PDZK1 KOmice: PDZK1 KOmice
exhibit essentially normal levels of SR-BI expression in steroidogenic
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mice), and the ratio of plasma unesteriﬁed-to-esterifed cholesterol in
PDZK1 KO mice is not elevated [12].
Numerous studies have established that SR-BI protects against
atherosclerosis in the mouse [10,21,22]. For example, hepatic over-
expression of SR-BI suppresses atherogenesis in LDL receptor KO mice
[23,24] , and the combined inactivation of the apoE and SR-BI genes
(SR-BI/apoE double KO (dKO)) in mice results in dramatically
enhanced aortic root atherogenesis compared to the apoE KO mouse
[10,21]. It appears that SR-BI expression in both hepatocytes and bone
marrow-derived cells is atheroprotective [25–27]. Strikingly, the SR-
BI/apoE dKO mice exhibit CHD-like cardiac phenotypes, not normally
seen in apoE KO or other murine models of atherosclerosis [22,23,10].
These include occlusive coronary arterial atherosclerosis, myocardial
infarction, heart dysfunction (e.g., cardiomegaly, ECG abnormalities)
and premature death (~6 weeks of age) [10,18,21].
In the current study, we have shown that complete PDZK1
deﬁciency did not affect SR-BI expression in two types of extrahepatic
cells important for development of atherosclerosis, macrophages and
endothelial cells. Furthermore, we examined the effects of PDZK1
deﬁciency on atherosclerosis in apoE KO mice using PDZK1/apoE dKO
mice fed a high fat/high cholesterol (“Western”) atherogenic diet. Our
data show that PDZK1 is atheroprotective: inactivation of the PDZK1
gene increased aortic root atherosclerosis. However, unlike complete
SR-BI-deﬁciency in SR-BI/apoE dKO mice, PDZK1 deﬁciency in apoE
dKO mice did not result in development of occlusive coronary artery
disease, myocardial infarction or premature death.
2. Materials and methods
2.1. Animals
Animals used for ﬂow cytometric analyses of cell surface SR-BI expression and
activity were either on a 50% C57BL/6/50% 129-S4 background (SR-BI KO and matching
control wild-type animals [19]) or on a 129 SvEv background (PDZK1 KO and its
matching wild-type controls [28]). All animals used for ﬂow cytometric analyses were
fed a standard chow diet. ApoE deﬁcient mice (C57BL/6 background) were purchased
from Jackson Laboratories (Bar Harbor, ME), mated with PDZK1 KO mice (129 SvEv
background). The initial PDZK1/apoE dKO and apoE KO animals from this cross (50:50
C57BL/6:129SvEv background) were used for a pilot atherosclerosis study. Subse-
quently, we backcrossed these mice for 6 generations into the C57BL/6 background to
generate the PDZK1/apoE double knockout (dKO) and apoE single KO mice (~98.5%
C57BL/6/1.5% 129 SvEv background) used to collect the data shown in Table 1, Figs. 2
and 3 and described in detail in Results and Discussion. Genotypes were determined by
PCR using established protocols ([19,28] and Jackson Laboratories web site). For
analyses of lipoproteins and atherosclerosis, approximately 4-week-old animals were
fed a “Western diet” from Harlan Teklad (Madison, WI) containing 42% [wt/wt] fat and
0.15% [wt/wt] cholesterol for 3 months.
2.2. Flow cytometric analysis
2.2.1. Measurement of cell surface SR-BI levels
Marrow from femur bones was collected in Hank's balanced salt solution (HBSS).
Spleens and lungs were ground through a cell strainer in HBSS. Ground lung tissuesTable 1
Table 1 Plasma lipids in chow andWestern diet-fed apoE KO and PDZK1/apoE dKOmice
Diet Genotype
(sample size)
TC
(mg/dl)
UC
(mg/dl)
UC/TC TG
(mg/dl)
PL
(mg/dl)
Chow APOE KO (n=3) 451±16 149±5a 0.33±0.02b 41±5 280±15
PDZK1/APOE dKO
(n=6)
529±35 204±10a 0.39±0.02b 54±10 323±16
Western APOE KO (n=9) 1424±106 473±56c 0.33±0.02d 50±9 511±32 e
PDZK1/APOE dKO
(n=8)
1521±126 688±67c 0.45±0.03d 59±10 661±42 e
Four-to-ﬁve month old animals were fasted for 4 hours prior to sample collection. TC:
total cholesterol, UC: unesteriﬁed cholesterol, TG: triglycerides and PL: phospholipids.
Values are represented as mean±standard error. Statistical signiﬁcance was determined
by pairwise comparisons of each value from dKO mice with apoE controls within the
same diet by using unpaired Student's t test.
a, b, c, d, ePb0.05.were further processed by incubation with 2 ml of digestion buffer (HBSS containing
3 mg/ml of collagenase A (Roche, Mannheim, Germany) and 0.5% fatty acid-free BSA) at
37 °C for 1 h. Numbers of total live cells from the lung and spleen were counted by
trypan blue exclusion after lysis of red blood cells. Cells (1×106) were stained with KKB-
1 anti-SR-BI rabbit antiserum35 (a generous gift from Karen Kozarsky from
GlaxoSmithKline), or with non-immune normal rabbit serum (Invitrogen, Carlsbad,
CA) as a negative control, followed by staining with anti-rabbit IgG-PE (Sigma) in
conjunction with cell type-speciﬁc, ﬂuorochrome-conjugated antibodies. These cell
type-speciﬁc antibodies are anti-Gr-1-FITC and anti-CD11b-APC antibodies for macro-
phages, anti-CD45-Alexa 488 and anti-CD31-APC antibodies for lung endothelial cells,
anti-CD19-FITC antibodies for B cells, anti-TCRβ-APC antibodies for T cells, and anti-
DX5-FITC antibodies for NK cells (purchased from BD Biosciences, San Jose, CA and
BioLegend, San Diego, CA). Samples were analyzed on a FACSCalibur™ ﬂow cytometer
(BD Biosciences) with FlowJo software (Tree Star Inc., Ashland, OR). Analyses were gated
on CD11b positive and Gr-1 medium cells for macrophages and on CD31 high and CD45
negative cells for lung endothelial cells. The relatively high, SR-BI-independent levels of
ﬂuorescence detected in macrophages and endothelial cells were due to using ﬂow
cytometer setting optimized for detection of the relatively low SR-BI levels and to high
intrinsic autoﬂuorescence exhibited by these cell types.
2.2.2. Measurement of DiI-HDL uptake
Cells (1×106) from bone marrow and spleens were washed twice with RPMI 1640,
followed by incubation with 100 µl of DiI-HDL (5 µg protein/ml [8]) containing medium
(RPMI 1640 with 0.5% fatty acid-free BSA) at 37 °C for 5 h. Antibody staining and ﬂow
cytometric analysis were performed as described above except the SR-BI antiserum and
anti-rabbit IgG antibody were omitted.
2.3. Morphologic and biochemical analyses
Mice were anesthetized. Blood was obtained by cardiac puncture using heparinized
syringes and centrifuged to obtain plasma. Hearts were excised after a short in vivo
perfusion with PBS and frozen in OCT compound. Frozen sections (10 µm) were stained
with Oil Red O as previously described [10]. Atherosclerotic lesions were measured by
planimetry as the sum of the cross-sectional areas using image measure/SPOT software
(Diagnostics Instruments, Sterling Heights, MI) in the aortic root as previously
described [10]. Immunoblots were performed as previously described [19]. Brieﬂy,
total liver samples (40–50 µg of protein/sample) were size-fractionated by 10% SDS-
PAGE and immunoblotted on nitrocellulose membranes with either polyclonal
antipeptide antibodies for SR-BI [8] or for actin (used as protein loading control,
Sigma, St Louis, MO). Antibody binding to protein samples was visualized by enhanced
chemiluminescence using Super Signal West Pico Luminal reagents (Pierce, Rockford,
IL). To semi-quantitatively determine the relative amounts of SR-BI, tissue lysates were
serially diluted, subjected to electrophoresis/immunoblotting and the relative inten-
sities of the signals were compared by visual inspection.
Cholesterol, unesteriﬁed cholesterol, phospholipids and triglycerides were mea-
sured using kits (Wako Chemical, Richmond, VA). FPLC size fractionation of plasma
lipoproteins was performed as previously described [29], except that previously frozen
plasma samples were used to determine the UC:TC ratios across FPLC fractions (Fig. 2C)
(n=4–5). A value of Pb0.05 between experimental groups was considered to represent
a signiﬁcant difference using a 2-tailed, unpaired Student's t test. Reported values
represent mean±standard error of the mean.
3. Results
Because macrophages and endothelial cells have been implicated
in atherogenesis [30], we compared SR-BI expression on the surfaces
of these cells from wild-type and PDZK1 KO mice by ﬂow cytometry
using anti-SR-BI polyclonal antibody KKB-1 [31] and antibodies
speciﬁc for each cell type as described in Materials and methods. To
do this, we ﬁrst compared the intensity of staining with an anti-SR-BI
antibody, or a control non-immune serum, of cells from wild-type
mice and those isolated from SR-BI KO mice (negative controls) to
determine if there were any detectable expression on a variety of
types of cells, including NK cells and B- and T-lymphocytes isolated
from spleen, monocytes/macrophages from both spleen and bone
marrow and endothelial cells isolated from lung. Robust SR-BI
expression was detected on macrophages and endothelial cells from
wild-type, but not SR-BI KO, mice (Fig. 1A and B, left panels), but little
or none on B cells, T cells and NK cells (not shown). These results are
consistent with previous reports of SR-BI expression in macrophages
and endothelial cells [32,33].
We next compared SR-BI surface expression on macrophage and
endothelial cells isolated from wild-type and PDZK1 KO mice using
either the speciﬁc anti-SR-BI antibody or control non-immune serum.
The SR-BI-speciﬁc antibody staining intensities of cells fromwild-type
Fig. 1. Inﬂuence of PDZK1 on SR-BI expression and function in macrophages and endothelial cells. SR-BI expression (shown as histograms of relative ﬂuorescence intensity) in splenic
macrophages (A) and lung endothelial cells (B) was examined by ﬂow cytometric analysis using as a primary antibody either the anti-SR-BI antibody KKB-1 (‘αSR-BI’, thick lines) or
non-immune control normal rabbit serum (‘control’, thin lines). SR-BI expression in cells from wild-type (WT) mice is represented by black lines, whereas that from SR-BI KO (left
panels) or PDZK1 KO (right panels) mice are represented with gray lines. Results from two pooled mice per group are shown (Panels A, B) and are consistent with independent
experiments using two individualmice. In panel A (left) the results from SR-BI KOwith control serum (thin gray line) overlapswith SR-BI KOwith anti-SR-BI antibody (thick gray line).
C. SR-BI function was measured by ﬂow cytometry as the uptake of the lipophilic dye DiI from DiI-labeled HDL by splenic macrophages. SR-BI lipid uptake activity (cellular DiI
accumulation) in macrophages fromwild-type mice is represented by black lines, whereas that from SR-BI KO (left panels) or PDZK1 KO (right panels) mice are represented with gray
lines. Results shown are from representative individual mice (n=2). 100% cell number ~1–2×103.
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staining intensity was observed with the control non-immune serum,
indicating that the level of SR-BI surface expression was not
signiﬁcantly altered by loss of PDZK1 expression (Fig. 1, panels A and
B, right panels). [Preliminary studies with dendritic cells gave results
similar to those with macrophages.] When bone marrow-derived
(n=3) or splenic (n=2) macrophages were incubated in culture with
HDL labeled with a ﬂuorescent lipid, DiI, there was similar uptake of
DiI by macrophages isolated from wild-type and PDZK1 KO mice, but
signiﬁcantly lower uptake by macrophages from SR-BI KO mice (not
shown and Fig. 1C). This result suggests that the SR-BI-dependent
uptake of lipid from DiI-HDL was not impaired in macrophages from
PDZK1 KOmice, and thus that the SR-BI expressed by PDZK1-negative
macrophages exhibited apparently normal lipid transport activity.
These data suggest that any effects of PDZK1 deﬁciency on athero-
sclerosis (see below) would be unlikely to be a consequence loss of SR-
BI activity by macrophages.To examine the effects of PDZK1 on lipoprotein metabolism and
atherosclerosis in atherosclerosis-prone apoE KO mice, we crossed
PDZK1 KO to apoE KO mice and subjected the PDZK1/apoE dKO mice
and control apoE single KO mice to an atherogenic Western diet for
3 months. All of the mice remained healthy throughout the feeding
period, and at the end of this period their body weights did not differ
signiﬁcantly (36.1±1.1 g (n=9) versus 34.7±1.2 g (n=8) for apoE KO
and PDZK1/apoE dKO mice, respectively, P=0.38).
We previously reported that hepatic SR-BI protein levels are
reduced by ~95% in PDZK1 KOmice relative towild-type controls [12].
However the inﬂuence of PDZK1 deﬁciency on hepatic SR-BI in apoE
KO mice fed an atherogenic Western diet was unknown. The
immunoblot in Fig. 2A shows that there was a dramatic reduction
(~93%) in hepatic SR-BI protein levels by PDZK1 deﬁciency in apoE KO
mice fed either a standard chow diet (left) or an atherogenic Western
diet (right). In otherwise wild-type mice fed a standard chow diet,
such a large PDZK1-dependent drop in hepatic SR-BI levels results in
Fig. 2. Immunoblot analysis of hepatic SR-BI expression and lipoprotein cholesterol
proﬁles from apoE KO and PDZK1/apoE dKO mice. Mice were fed a standard chow
(panel A) or a high fat/high cholesterol “Western” diet (panels A, B and C) for three
months. A. Livers were harvested and subjected to immunoblotting using anti-SR-BI
and anti-actin antibodies as described in Materials and methods. B. Plasma harvested
from individualWestern diet-fed animals was size-fractionated using FPLC and the total
cholesterol (note change of scale in inset) contents of the fractions (mg/dl plasma) were
determined by enzymatic assay. Proﬁles averaged from six apoE KO (ﬁlled circles) and
six PDZK1/apoE dKO (open circles) mice are shown. Approximate elution positions of
human VLDL, IDL/LDL and HDL are indicated. C. Unesteriﬁed cholesterol (UC) and total
cholesterol (TC), and the corresponding unesteriﬁed-to-total (UC:TC) cholesterol ratios,
were determined for FPLC fractions 6–25 ( averages from ﬁve apoE KO (ﬁlled circles)
and four PDZK1/apoE dKO (open circles) mice). UC values beyond fraction 25 were
below the limits of detection. Error bars represent SEM. See alsoMaterials andmethods.
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lipoprotein particles [12]. This was not the case for apoE KO mice fed
the Western diet.
Fig. 2B shows representative plasma lipoprotein total cholesterol
proﬁles (FPLC size exclusion chromatography of plasma) of apoE single
KO and PDZK1/apoE dKO mice fed with the Western diet. The plasma
lipoprotein total cholesterol proﬁles were virtually identical. They
were also similar to previously reported proﬁles of apoE KO mice fed
with atherogenic diets [34,35], with the largest peak of cholesterol inVLDL-size particles, a broad peak in the IDL/LDL-size range and very
little in the HDL-size range. The abundance of the major apolipopro-
tein of HDL, apoA-I, from the normal-size pooled VLDL, IDL/LDL and
HDL fractions (fractions 5–7, 14–16 and 35–37, respectively) was
analyzed by immunoblotting and was found to be similar between the
two groups (n=3, not shown). This result differs from that for SR-BI/
apoE dKOs that do not have apoA-I in the normal HDL-size region,
because most of the HDL is abnormally large [10]. Fig. 2C shows that
differences in the UC:TC ratios of the FPLC fractions 6–25 reﬂected
differences in the overall UC:TC ratio difference in plasma (see below).
(UC content was below the limit of detection beyond fraction 25, and
thus the ratios could not be determined (not shown)). In contrast, SR-
BI/apoE dKO animals have very high UC:TC ratios (~0.8) in the VLDL
and IDL/LDL-size fractions and total plasma (AY, OK, MK, unpublished
observations). FPLC analysis of plasma from mice fed a standard chow
diet (not shown) showed a total cholesterol proﬁle in apoE single KO
mice similar to that previously reported [34,35] and, as expected [12] a
small increase in the apparent size of the HDL peak in the plasma from
PDZK1/apoE dKO mice.
Quantitative analysis of plasma lipids fromapoE KO and PDZK1/apoE
dKOmice fed either a standard chow orWestern diets for three months
are shown in Table 1. As expected, the plasma cholesterol values were
substantially higher in mice fed the Western diet. There were no
signiﬁcant differences in the amounts of plasma total cholesterol
between apoE KO and PDZK1/apoE dKOmicewith either diet ; however,
the level of plasma unesteriﬁed cholesterol (UC) was increased by 45%
(Western diet, P=0.026) or 37% (standard chow diet, P=0.009) in the
PDZK1/apoE dKOmice relative to apoE single KOmice . Formice fed the
Western diet, this difference is reﬂected in a 36% increase in the UC:TC
ratios (P=0.003). When fed with a Western diet, the increase in UC:TC
was accompanied by a 29% increase in the relative amount of plasma
phospholipids (P=0.01). There were no statistically signiﬁcant differ-
ences observed for the triglycerides on either diet or for the plasma
phospholipids on the chow diet.
We have previously reported that SR-BI single KO and SR-BI/apoE
dKO mice – but not PDZK1 KO or apoE KO mice – fed with a standard
chow diet exhibit abnormally high UC:TC ratios [18], due at least in
part to the abnormally large HDL particles failing to serve as effective
substrates for the plasma cholesterol esterifying enzyme lecithin:
cholesterol acyl transferase [29,36]. Apparently the additional stress
due to the apoE deﬁciency induces the abnormally high UC:TC ratio
(as well as high UC and phospholipid levels) in the PDZK1/apoE dKO
mice. The mechanism underlying this effect, however, is not clear.
After feeding the mice a Western diet for 3 months, we measured
atherosclerotic plaque areas at the level of the aortic root in Oil Red O-
stained frozen sections. Both apoE single KO and PDZK1/apoE dKO
mice showed signiﬁcant amounts of atherosclerosis (Fig. 3). Visual
inspection of histologic tissue sections revealed that plaques from the
aortic sinuses of the apoE single KO and PDZK1/apoE dKO animals
were composed primarily of macrophage-derived foam cells and that
smooth muscle cells did not appear to represent a signiﬁcant cell
population in the lesions. There were no apparent differences in the
general morphologies of the plaques in the apoE single KO and PDZK1/
apoE dKO mice. However, the areas of plaque were signiﬁcantly larger
(57%) in the PDZK1/apoE dKO mice (0.493±0.023 mm2) than in the
apoE KO mice (0.314±0.024 mm2, Pb0.0001). Increased atherosclero-
sis in PDZK1/apoE dKO compared to apoE KO mice was also observed
in a pilot study using mice on a 50:50 C57BL/6:129SvEv background
(P=0.015). Thus, PDZK1 is atheroprotective in apoE KO mice.
We have previously reported that apoE KO mice bearing an
homozygous null mutation in the SR-BI gene (SR-BI/apoE dKO mice)
exhibit a number of the hallmarks of CHD not usually observed in apoE
single KO mice, including occlusive coronary arterial atherosclerosis,
cardiomegaly, myocardial infarctions, cardiac dysfunction and pre-
mature death [10,21]. We therefore examined Masson's trichrome-
stained sections of the hearts (mid-portion of the myocardium and
Fig. 3. Aortic root atherosclerosis in Western diet-fed apoE KO and PDZK1/apoE KO
mice. A–B. Representative cross-sections of Oil red O-stained aortic root lesions.
Magniﬁcation, ×20. C. Average lesion areas (mm2, horizontal lines) were: apoE KO,
0.314±0.024 (n=9); PDZK1/apoE dKO, 0.493±0.023 (n=8), ⁎Pb0.0001. D–E. Represen-
tative sections of hearts stained with Masson's trichrome, showing no evidence of
either ﬁbrosis or myocardial infarction. Magniﬁcation, ×4.5.
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and control apoE KO (n=8) mice to determine if the reduced hepatic
expression of SR-BI due to the PDZK1 deﬁciency resulted in similar
CHD pathogenesis. Neither PDZK1/apoE dKO or apoE KO mice
exhibited ﬁbrosis, myocardial infarction, leukocyte inﬁltration or
coronary arterial occlusions, as do SR-BI/apoE dKO mice (Fig. 3 D,E).
Furthermore, there was no gross difference in heart size with or
without PDZK1 expression. In addition, we did not detect premature
death or gross abnormalities in behavior or general health in either
standard lab chow-fed or atherogenic diet-fed PDZK1/apoE dKO mice.
4. Discussion
In the current study, we found that there was a 57% increase in
aortic root atherosclerosis in PDZK1/apoE dKO mice relative to apoEKO mice. It seems likely that the reduced hepatic expression of SR-BI
in PDZK1/apoE dKO mice relative to apoE KO mice, and the
consequent effects on lipoprotein metabolism (potentially reduced
reverse cholesterol transport and an increased UC:TC ratio (increased
UC and phospholipids) in plasma lipoproteins) contributed to the
enhanced atherogenesis in the dKOmice. However, other mechanisms
may also contribute to the enhanced atherosclerosis. For example,
effects of PDZK1 deﬁciency on the expression of SR-BI in extrahepatic
tissues may have made a contribution. We previously reported [12]
that in PDKZ1 KO mice fed a standard chow diet, SR-BI expression is
modestly (50%) reduced in the intestines, where SR-BI appears to be
expressed primarily on the apical surface of enterocytes [37]. It does
not seem likely that a modest reduction in intestinal SR-BI would
inﬂuence atherogenesis other than via its inﬂuence on lipoprotein
metabolism.
Two types of extrahepatic cells that do directly inﬂuence athero-
sclerosis are macrophages and endothelial cells. We found that surface
expression of SR-BI onbothmacrophages (derived frombonemarrowor
spleen) and endothelial cells (derived from lung) was not reduced in
PDZK1KOmice compared to wild-type controls. Furthermore, the SR-BI
expressed by macrophages appeared to function normally, as indicated
by its ability tomediate uptake of lipid fromHDL. Kimura et al. have also
reported that SR-BI surface expression is not impaired in endothelial
cells in which PDZK1 expression has been abrogated by siRNA [38].
However, they also reported that, despite the normal level of SR-BI
surface expression, at least one activitymediated by SR-BI in endothelial
cells,HDL-dependent activationof eNOS,was signiﬁcantly suppressed in
the absence of PDZK1 expression. Thus, it remains possible that loss of
SR-BI-mediated activity in endothelial cells may contribute to the
increased atherosclerosis observed in apoE KO mice when the PDZK1
gene is inactivated.
Strikingly, PDZK1/apoE dKO mice do not exhibit the severe
occlusive atherosclerotic CHD seen in SR-BI/apoE dKO mice. There
are several potential–notmutually exclusive–explanations. There is no
expression of SR-BI, or its minor alternatively spliced isoform SR-BII
[16] (see below), in any tissue of SR-BI KO mice [19]. In contrast, while
PDZK1 KO mice express only residual levels of SR-BI in the liver (b5%),
they express about 50% of wild-type levels in the intestines and
apparently normal levels in steroidogenic organs (e.g. adrenal glands)
[12], macrophages and endothelial cells (this study, also see [39]). Loss
of SR-BI expression in adrenal glands in SR-BI KO mice results in
dramatically reduced adrenal cholesteryl ester stores [19] and thus
might inﬂuence adrenocortical function [40] and its moderating
effects on inﬂammation [41]. A recent report by Cai et al. strongly
supports this suggestion [42]. In turn, this potential pathology in SR-
BI/apoE dKO, but not PDZK1/apoE dKO, mice may stimulate the
development of occlusive coronary arterial atherosclerosis.
Another noteworthy difference is that hepatic expression of the
SR-BII splice form, which mediates endocytosis of ligands [16,17,43], is
normal in PDZK1 KO mice [12], but absent in SR-BI KO mice. Thus, just
as differences in SR-BI expression in hepatic and extrahepatic tissues
between PDZK1/apoE dKO and apoE KO mice may account for the
increased atherosclerosis in PDZK1/apoE KO mice, so may distinct
differences between PDZK1/apoE and SR-BI/apoE dKO mice in SR-BI/
SR-BII expression in hepatic and extrahepatic tissues account for their
dramatic differences in occlusive CHD. Previous studies have shown
that even very low levels of expression of genes involved with
atherosclerosis can have a profound effect on pathogenesis. For
example, very low expression of apoE has been shown to dramatically
alter atherogenesis in several murine systems [44–50].
In conclusion, the current studies show that a functional PDZK1gene,
most likely because of its role as the adaptor protein for SR-BI, is
atheroprotective in mice. PDZK1 is the second adaptor protein for an
hepatic lipoprotein receptor to be shown to be atheroprotective, theﬁrst
being the human LDL receptor adaptor ARH [1,5,51]. Individuals with
inactivating mutations in the ARH gene exhibit phenotypes similar to
315O. Kocher et al. / Biochimica et Biophysica Acta 1782 (2008) 310–316those of patients with familial hypercholesterolemia (FH), in which the
low density lipoprotein receptor (LDLR) is inactivated [1–3,5]. Further
studies will be necessary to determine if genetic variations in PDZK1 in
humans inﬂuence the incidence of atherosclerosis and CHD.
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